# Clinical Trials Data EGFR - Document 140

# Analysis of Plasma Tumor DNA in Lung Cancer Patients

## Clinical Trial: https://clinicaltrials.gov/study/NCT01930474

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Have a histologically or cytologically confirmed diagnosis of non-small cell lung cancer\n\* Have molecular evidence of genetic alterations in tumor sample (eg. EGFR mutations, ALK fusions)\n\* Patients must have given written informed consent\n\nExclusion Criteria:\n\n\* Patients who refuse the blood samplings",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
"stdAges": [  
"CHILD",  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "The non-small cell lung cancer patients who will be or have been treated with chemotherapy (including target agents)",

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the eligibility criteria provided for the clinical trial, a patient with an EGFR gene mutation would be eligible to participate. The inclusion criteria specifically mention the requirement for molecular evidence of genetic alterations in the tumor sample, such as EGFR mutations or ALK fusions. This means that patients who have an EGFR gene mutation meet this particular inclusion criterion. Additionally, as long as the patient meets the other criteria and does not fall under any exclusion criteria, they would be eligible for the trial.